Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.

Ceralasertib plus durvalumab does not improve overall survival compared to docetaxel in patients with locally advanced/metastatic NSCLC.

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or ...

Combining durvalumab (Imfinzi) with stereotactic body radiotherapy (SBRT) appeared to reduce tumor progression among patients ...

CHICAGO -- Consolidation treatment with durvalumab (Imfinzi) following concurrent chemoradiotherapy significantly improved both overall survival (OS) and progression-free survival (PFS) in patients ...

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 Patients (n = 1,013) with EGFR/ALK ...

A regulatory decision on the application is expected during the fourth quarter of 2024. The Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License ...

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared ...

Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival was 55 ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard ...

In the accompanying article, Jani et al 2 provide the necessary complement to this clinical success by examining economic value. Their cost-utility analysis, grounded in ADRIATIC outcomes, addresses ...